Company intelligence / Profile preview

JLS Fund

New York, New York, United States

Ownership: Private
Employees: ~11
Development stage: Other

Overview

JLS Fund is an active NY-based venture capital fund investing in early-stage companies developing plant-based and psychedelic-inspired therapeutics for mental health and neurological conditions. Clinical results in the portfolio range from pre-clinical to late-stage, with Gilgamesh's 'Bretisilocin' having reached a $1.2B acquisition after positive clinical milestones.

Therapeutic areas: NeurologyPsychiatry
Modalities: Small moleculePsychedelic compoundBiologicMonoclonal antibody
Industry: Investors

Partnerships

AbbVie (via Gilgamesh Pharmaceuticals acquisition)

Beyond the preview

Go deeper on JLS Fund.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JLS Fund.

Explore the full profile